Leader Capital Markets Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the top cheap pharmaceutical stocks to buy now. Leader Capital Markets analyst Sabina Levi maintained a Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on August 1, setting a price target of ILA9,300.00.

Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.

The rating update followed Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) release of its fiscal Q2 2025 results on July 30. The company reported that it is on track for a 30% operating profit margin by 2027, in line with its Pivot to Growth Strategy.

Q2 2025 marked the 10th consecutive quarter of year-over-year revenue growth for Teva Pharmaceutical Industries Limited (NYSE:TEVA), with Q2 2025 revenue reaching $4.2 billion.

The company reported a GAAP diluted EPS of $0.24, while non-GAAP diluted EPS reached $0.66, reflecting a growth of $0.05 or 9% year-over-year. Free cash flow for the quarter also rose 47% year-over-year to $476 million.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments.

Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.